B·R·A·H·M·S explores, develops and produces new diagnostic test procedures to improve the diagnosis, and thereby the treatment, of life-threatening illnesses. This takes place with over 400 employees, on the basis of their own patented biomarkers, and leads to medically and economically superior diagnostic insights for patients and medical professionals. B·R·A·H·M·S products reach customers in over 65 countries around the world and are leaders in their specialized markets.

Takeda Pharmaceutical Company Ltd (武田薬品工業株式会社 Takeda Yakuhin Kōgyō Kabushiki-gaisha) is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following merger with Shire). The company has over 30,000 employees worldwide and achieved 16.2 billion USD in revenue during the 2012 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Takeda Oncology. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States.

Tianjin Institute of Pharmaceutical Research Co., Ltd. engages in the in the development of various new products such as innovative drugs, generic drugs, new preparations, traditional Chinese medicines, and biological drugs with particular emphasis on the engineering and industrialization of new technologies to meet drug registration requirements. The company was founded in 1959 and is headquartered in Tianjin, China.

Tianjin Taipu Pharmaceutical Co., Ltd., established on 2010-12-16, Business scope includes pharmaceutical production(Carry out business activities with a license);Pharmaceutical Intermediates,Chemical raw materials(Does not contain dangerous chemicals and flammable and explosive precursors)manufacturing,processing,Sales;Self-operated and agent goods and technology import and export;Raw and auxiliary materials(Free of Hazardous Chemicals,Flammable and explosive precursors),Equipment,Instrumentation,Sales of spare parts and company-produced products;Own house rental;property management;biology,Development of medical technology and products,consult,transfer,Serve.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Wellesley Pharmaceuticals ensures that the ability of Nocturol to reduce and sometimes eliminate nocturia symptoms can be disseminated. Wellesley Pharmaceuticals is in the development of an innovative, patented drug for treating Nocturia (frequent urination at night). Currently, there are no drugs on the market focused on nocturia and Wellesley plans to be first to market in the space. They believe that their proprietary drug, Paxerol, positions them to be the industry leader, addressing a massive unmet clinical need. Paxerol offers a significant advancement in terms of mechanism of action relative to existing indirect treatments of nocturia and should allow them to provide relief to hundreds of millions of people.

Manufactures and sells pharmaceuticals

The Max Planck Society for the Advancement of Science (German: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V.; abbreviated MPG) is a non-governmental and non-profit association of Research Institutes publicly funded by the federal and the state governments of Germany. Additionally, the Max Planck Society and its Institutes receive third party funding from public and private contributions and from the European Union. The world leading organization is named in honor of its former president, theoretical physicist Max Planck. The 86 Institutes and Research Facilities of the Max Planck Society (as of 2020) conduct basic research in the natural sciences, life sciences, social sciences, and the arts and humanities. They have a total staff of approximately 24,000 permanent employees, including 15,000 scientists, and around 5,000 non-tenured scientists and guests. As of December 31, 2018, the proportion of female employees was 44.4 percent. The Max Planck Society (with its 86 Max Planck Institutes) has a world-leading reputation as a science and technology research organization, with more than 33 Nobel Prizes awarded to its scientists, and is widely regarded as one of the foremost basic research organizations in the world.

Otsuka Holdings operates in pharmaceuticals, nutraceuticals, and consumer products. The business activity of the company includes providing healthcare solutions in the areas of the nervous system, oncology, cardiovascular system, respiratory system, infectious disease, and others. The company engages in the research and development of functional foods and beverages, such as electrolyte drinks, nutritional foods, soy snacks, and dietary foods.

Part of Xenetic Biosciences, Inc., Lipoxen Technologies Ltd. is a company headquartered in London, UK. The firm specializes in product development in the pharmaceutical industry. It was founded in 1997.\nThe company says this about itself: Lipoxen Technologies Ltd specializes in development of drug delivery systems and proprietary products in the fields of protein drugs, vaccines and oncology.

Part of Merck & Co., Inc., Organon Laboratories Ltd. is a British company located in Hoddesdon focused on pharmaceutical preparations.

NsGene A/S identifies neurotrophic proteins with therapeutic effects in the nervous system. It is a biotechnology company that focuses primarily on neurodegenerative disorders. The firm provides technologies that target protein therapeutics across the blood-brain-barrier and directly to diseased nerve cells. It develops therapeutic products for multiple indications with high medical needs including Alzheimer’s disease, Parkinson's disease, deafness, neuropathic pain, epilepsy, cortico-basal degeneration, and Huntington’s disease. The company was founded by Lars Ulrik Wahlberg and Teit Eliot Johansen in 1999 and is headquartered in Ballerup, Denmark.

Janssen Pharmaceutica is a pharmaceutical company headquartered in Beerse, Belgium and owned by Johnson & Johnson. It was founded in 1953 by Paul Janssen. In 1961, Janssen Pharmaceutica was purchased by New Jersey-based American corporation Johnson & Johnson, and became part of Johnson & Johnson Pharmaceutical Research and Development (J&J PRD), now renamed to Janssen Research and Development (JRD), which conducts research and development activities related to a wide range of human medical disorders, including mental illness, neurological disorders, anaesthesia and analgesia, gastrointestinal disorders, fungal infection, HIV/AIDS, allergies and cancer. Janssen and Ortho-McNeil Pharmaceutical have been placed in the Ortho-McNeil-Janssen group within Johnson & Johnson Company.

Baxalta, Inc. engages in the research, development, and manufacture of biopharmaceutical products. Its portfolio includes treatments for hemophilia, bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns, and shock. The company was founded on March 13, 2015 and is headquartered in Chicago, IL.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Taisho Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceutical products. It operates through the following divisions: Self-Medication, Prescription Pharmaceutical and Overseas Development. The Self-Medication division deals with the research, development, and production of over-the-counter (OTC) drugs, medical supplies, food for specific health use, and hygiene products. The Prescription Pharmaceutical division handles research and development of new drugs in the fields of central nervous system diseases, metabolic diseases, infectious diseases, and inflammatory diseases. The Overseas Development division markets energy drinks and OTC pharmaceuticals overseas. The company was founded on October 12, 1912 and is headquartered in Tokyo, Japan.

Develops and manufactures drugs related to immunology, neurobiology and oncology

Yamanouchi Pharmaceutical Co. Ltd. manufactures and markets drugs, quasi-drugs and medical devices. It used to promote collaboration with other pharmaceutical companies as well as bioventure companies and academia to raise the quality and speed of its R&D activities. It was founded in 1923. The company was headquartered in Tokyo, JP